These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1937296)

  • 1. Cutaneous effects of transdermal levonorgestrel.
    Friend DR; Phillips SJ; Hill JR
    Food Chem Toxicol; 1991 Sep; 29(9):639-46. PubMed ID: 1937296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal delivery of levonorgestrel. VII. In vivo studies.
    Friend DR; Catz P; Phillips S
    Contraception; 1989 Jul; 40(1):73-80. PubMed ID: 2505971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal delivery of levonorgestrel. V. Preparation of devices and evaluation in vitro.
    Friend DR; Catz P; Heller J; Okagaki M
    Pharm Res; 1989 Nov; 6(11):938-44. PubMed ID: 2512569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal delivery of levonorgestrel.
    Friend DR
    Med Res Rev; 1991 Jan; 11(1):49-80. PubMed ID: 1899713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal delivery of contraceptives.
    Friend DR
    Crit Rev Ther Drug Carrier Syst; 1990; 7(2):149-86. PubMed ID: 2272099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluations of transdermal levonorgestrel.
    Catz P; Friend DR
    Drug Des Deliv; 1990 May; 6(1):49-60. PubMed ID: 2127673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against ({+/-}) anatoxin-a poisoning.
    Banerjee S; Chattopadhyay P; Ghosh A; Pathak MP; Singh S; Veer V
    Int J Toxicol; 2013 Jul; 32(4):308-13. PubMed ID: 23696561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance.
    Chien YW; Chien TY; Bagdon RE; Huang YC; Bierman RH
    Pharm Res; 1989 Dec; 6(12):1000-10. PubMed ID: 2516312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product.
    Jordan WP; Atkinson LE; Lai C
    Clin Ther; 1998; 20(1):80-7. PubMed ID: 9522106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal delivery of levonorgestrel. IV: Evaluation of membranes.
    Friend DR; Catz P; Heller J; Okagaki M
    J Pharm Sci; 1989 Jun; 78(6):477-80. PubMed ID: 2503604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on in vitro and in vivo transdermal flux enhancement of methotrexate by a combinational approach in comparison to oral delivery.
    Prasad R; Anand S; Khar RK; Dinda AK; Koul V
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1281-92. PubMed ID: 19832628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic enhancement of papaverine transdermal gel for erectile dysfunction.
    Wen MM; El-Kamel AH; Khalil SA
    Drug Dev Ind Pharm; 2012 Aug; 38(8):912-22. PubMed ID: 22080854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative assessment of 24-hr primary skin irritation test and human patch test data with in vitro skin irritation tests according to OECD Test Guideline 439 (for quasi-drugs in Japan).
    Sugiyama M; Akita M; Alépée N; Fujishiro M; Hagino S; Handa Y; Ikeda H; Imai N; Jitsukawa S; Katoh M; Kurihara K; Kyotani D; Nomura S; Okamoto Y; Okumura H; Omori T; Sugibayashi K; Todo H; Toyoda A; Ohno Y
    J Toxicol Sci; 2018; 43(12):751-768. PubMed ID: 30518713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced transdermal delivery with less irritation by magainin pore-forming peptide with a N-lauroylsarcosine and sorbitan monolaurate mixture.
    Lee H; Park J; Kim YC
    Drug Deliv Transl Res; 2018 Feb; 8(1):54-63. PubMed ID: 29090413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabrication and evaluation of polymeric films for transdermal delivery of pinacidil.
    Aqil M; Ali A; Sultana Y; Najmi AK
    Pharmazie; 2004 Aug; 59(8):631-5. PubMed ID: 15378854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
    Yang Z; Teng Y; Wang H; Hou H
    Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of transdermal therapeutic formulation of CNS5161, a novel NMDA receptor antagonist, by utilizing pressure-sensitive adhesives II: improved transdermal absorption and evaluation of efficacy and safety.
    Naruse M; Ogawara K; Kimura T; Konishi R; Higaki K
    Eur J Pharm Sci; 2014 Feb; 52():86-94. PubMed ID: 24215737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of vehicles on the human dermal irritation potentials of allyl esters.
    Politano VT; Isola DA; Lalko J; Api AM
    Int J Toxicol; 2006; 25(3):183-93. PubMed ID: 16717034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.